TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

Inclusion Criteria: * ≥ 18 years of age. * Signed written informed consent. * Histologically confirmed advanced melanoma that is either stage III (unresectable) or stage IV (metastatic). * Absence of a BRAF V600 mutation as determined by a validated test. * In case of mucosal or acral melanoma, absence of a cKIT (proto-oncogene c-Kit) mutation as determined by a validated test. * Presence of archival melanoma tissue of possibility of new biopsy for mutational testing. * Subjects must have failed at least one prior systemic treatment with immune checkpoint inhibitors: CTLA-4 (cytotoxic T-lymphocyt antigen 4) blocking immune checkpoint inhibitors (ipilimumab or other experimental anti-CTLA-4 antibodies), PD-1 (programmed cell death 1) blocking immune checkpoint inhibitors (pembrolizumab, nivolumab or other experimental anti-PD-1 antibodies) and/or PD-L1 (programmed cell death ligand 1) blocking immune checkpoint inhibitors (avelumab, atezolizumab, durvalumab or other experimental anti-PD-L1 antibodies). Progression of disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, or per immune related response criteria (irRC) must have been documented during this treatment. Patients who are not able to undergo such treatment are also eligible. * The presence of at least one measurable lesion per RECIST, version 1.1 * Interval between the date of the last administration of prior therapy for melanoma and the date of recruitment: a. ≥12 weeks following the date o…